ABEO - שווי פירמה כולל abeonatherapeutics.com

The price action visualization for Abeona Therapeutics (ABEO) on GURU.Markets captures an Enterprise Value of 133.80. Abeona Therapeutics develops treatments for orphan diseases, implementing unambitious ESG standards by minimizing its carbon footprint and treating wastewater. The business relies on a unique gene therapy method that guarantees high profits, although international sanctions and logistical disruptions in Asia hinder the conduct of global clinical trials.

Abeona Therapeutics (ABEO) is striving for dominance in the recessive dystrophic epidermolysis bullosa gene therapy niche, making the enterprise value (EV) assessment critical as the company prepares to bring Pz-cel to market. This indicator aggregates market capitalization and net debt to determine the actual cost of acquiring the issuer, allowing investors to identify any overpayment for an asset in the venture growth category.